Cargando…

Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis

The sofosbuvir-velpatasvir single-tablet regimen (Epclusa) is a newly FDA-approved inhibitor of hepatitis C virus (HCV). This meta-analysis aimed to investigate the safety and efficacy of velpatasvir-sofosbuvir in the treatment of chronic HCV infection. METHODS: A comprehensive literature search of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Xiao-Dan, Fu, Xue, He, Yuan-Qun, Li, Chun-Yan, Guo, Meng, Qiao, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592351/
https://www.ncbi.nlm.nih.gov/pubmed/36281168
http://dx.doi.org/10.1097/MD.0000000000031183
_version_ 1784814905939984384
author Ren, Xiao-Dan
Fu, Xue
He, Yuan-Qun
Li, Chun-Yan
Guo, Meng
Qiao, Min
author_facet Ren, Xiao-Dan
Fu, Xue
He, Yuan-Qun
Li, Chun-Yan
Guo, Meng
Qiao, Min
author_sort Ren, Xiao-Dan
collection PubMed
description The sofosbuvir-velpatasvir single-tablet regimen (Epclusa) is a newly FDA-approved inhibitor of hepatitis C virus (HCV). This meta-analysis aimed to investigate the safety and efficacy of velpatasvir-sofosbuvir in the treatment of chronic HCV infection. METHODS: A comprehensive literature search of PubMed, Cochrane CENTRAL, EMBASE and Web of Science was conducted. Data from eligible studies were pooled in a fixed-effect meta-analysis model, using Open-Meta and RevMan software’s. RESULTS: Pooled data showed that velpatasvir-sofosbuvir achieved sustained virological response (SVR12) rates of 94.2% (95% CI 90.7–97.7%, P < .001) in 1277 patients. The addition of ribavirin did not significantly increase the SVR12 (RR = 1.03, 95%CI [0.95, 1.11]) in HCV genotype-1 patients and the SVR12 (RR = 1.09, 95%CI [0.86, 1.38]) in HCV genotype-2 patients. However, adding ribavirin significantly increased SVR12 (RR = 1.13, 95% CI [1.04, 1.23]) in genotype-3 patients. CONCLUSION: In conclusion, the 12-week regimen of sofosbuvir-velpatasvir was highly effective in HCV patients. Except for genotype-3, adding ribavirin was not associated with significant improvements in SVR12 rates.
format Online
Article
Text
id pubmed-9592351
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-95923512022-10-25 Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis Ren, Xiao-Dan Fu, Xue He, Yuan-Qun Li, Chun-Yan Guo, Meng Qiao, Min Medicine (Baltimore) 6600 The sofosbuvir-velpatasvir single-tablet regimen (Epclusa) is a newly FDA-approved inhibitor of hepatitis C virus (HCV). This meta-analysis aimed to investigate the safety and efficacy of velpatasvir-sofosbuvir in the treatment of chronic HCV infection. METHODS: A comprehensive literature search of PubMed, Cochrane CENTRAL, EMBASE and Web of Science was conducted. Data from eligible studies were pooled in a fixed-effect meta-analysis model, using Open-Meta and RevMan software’s. RESULTS: Pooled data showed that velpatasvir-sofosbuvir achieved sustained virological response (SVR12) rates of 94.2% (95% CI 90.7–97.7%, P < .001) in 1277 patients. The addition of ribavirin did not significantly increase the SVR12 (RR = 1.03, 95%CI [0.95, 1.11]) in HCV genotype-1 patients and the SVR12 (RR = 1.09, 95%CI [0.86, 1.38]) in HCV genotype-2 patients. However, adding ribavirin significantly increased SVR12 (RR = 1.13, 95% CI [1.04, 1.23]) in genotype-3 patients. CONCLUSION: In conclusion, the 12-week regimen of sofosbuvir-velpatasvir was highly effective in HCV patients. Except for genotype-3, adding ribavirin was not associated with significant improvements in SVR12 rates. Lippincott Williams & Wilkins 2022-10-21 /pmc/articles/PMC9592351/ /pubmed/36281168 http://dx.doi.org/10.1097/MD.0000000000031183 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 6600
Ren, Xiao-Dan
Fu, Xue
He, Yuan-Qun
Li, Chun-Yan
Guo, Meng
Qiao, Min
Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis
title Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis
title_full Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis
title_fullStr Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis
title_full_unstemmed Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis
title_short Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis
title_sort safety and efficacy of sofosbuvir-velpatasvir: a meta-analysis
topic 6600
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592351/
https://www.ncbi.nlm.nih.gov/pubmed/36281168
http://dx.doi.org/10.1097/MD.0000000000031183
work_keys_str_mv AT renxiaodan safetyandefficacyofsofosbuvirvelpatasvirametaanalysis
AT fuxue safetyandefficacyofsofosbuvirvelpatasvirametaanalysis
AT heyuanqun safetyandefficacyofsofosbuvirvelpatasvirametaanalysis
AT lichunyan safetyandefficacyofsofosbuvirvelpatasvirametaanalysis
AT guomeng safetyandefficacyofsofosbuvirvelpatasvirametaanalysis
AT qiaomin safetyandefficacyofsofosbuvirvelpatasvirametaanalysis